These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7562403)

  • 41. Stability of dexamethasone sodium phosphate in rat plasma.
    Samtani MN; Jusko WJ
    Int J Pharm; 2005 Sep; 301(1-2):262-6. PubMed ID: 16054309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of Budesonide-MMX in active ulcerative colitis.
    Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs.
    Cho H; Chung Y
    Arch Pharm Res; 2004 Jun; 27(6):662-9. PubMed ID: 15283470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
    Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
    Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].
    Caesar I; Gross V; Roth M; Andus T; Hohenberger W; Schölmerich J
    Med Klin (Munich); 1997 Jun; 92(6):358-62. PubMed ID: 9297069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats.
    Rodriguez M; Antúnez JA; Taboada C; Seijo B; Torres D
    J Pharm Pharmacol; 2001 Sep; 53(9):1207-15. PubMed ID: 11578103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Azo-reductase activated budesodine prodrugs for colon targeting.
    Marquez Ruiz JF; Kedziora K; O'Reilly M; Maguire J; Keogh B; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7573-7. PubMed ID: 23122819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.
    Yoshigae Y; Imai T; Aso T; Otagiri M
    Life Sci; 1998; 62(14):1231-41. PubMed ID: 9570338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments.
    Chanoine F; Grenot C; Heidmann P; Junien JL
    Drug Metab Dispos; 1991; 19(2):546-53. PubMed ID: 1676668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring novel colon-targeting antihistaminic prodrug for colitis.
    Dhaneshwar S; Gautam H
    J Physiol Pharmacol; 2012 Aug; 63(4):327-37. PubMed ID: 23070081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis.
    Nam J; Kim W; Lee S; Jeong S; Yoo JW; Kim MS; Jung Y
    J Drug Target; 2016; 24(5):468-74. PubMed ID: 26377354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria.
    Friend DR; Chang GW
    J Med Chem; 1984 Mar; 27(3):261-6. PubMed ID: 6699871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
    Hanauer SB; Robinson M; Pruitt R; Lazenby AJ; Persson T; Nilsson LG; Walton-Bowen K; Haskell LP; Levine JG
    Gastroenterology; 1998 Sep; 115(3):525-32. PubMed ID: 9721148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.
    Varshosaz J; Emami J; Fassihi A; Tavakoli N; Minaiyan M; Ahmadi F; Mahzouni P; Dorkoosh F
    Int J Colorectal Dis; 2010 Oct; 25(10):1159-65. PubMed ID: 20669022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
    Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
    Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
    J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
    Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Budesonide for the treatment of ulcerative colitis.
    Abdalla MI; Herfarth H
    Expert Opin Pharmacother; 2016 Aug; 17(11):1549-59. PubMed ID: 27157244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.
    Leopold CS; Friend DR
    J Pharmacokinet Biopharm; 1995 Aug; 23(4):397-406. PubMed ID: 8882747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rectal pharmacokinetics of budesonide.
    Dahlstrom K; Edsbacker S; Kallen A
    Eur J Clin Pharmacol; 1996; 49(4):293-8. PubMed ID: 8857075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.